Home > Products > Antibodies > Biosimilars

Research Grade Motavizumab (VK421036)

Price(USD): $
Spec:
  • 100ug
  • 1mg
Number:
Contact us
  • Overview
  • Images
  • References
  • Datasheet
Overview
Catalog No.VK421036
DescriptionMotavizumab (MEDI-524, NUMAX, NISTmAb) is a second generation monoclonal antibody (mAb) derived from palivizumab (Synagis) using affinity maturation techniques. Motavizumab is currently undergoing US Food and Drug Administration review as a treatment for respiratory syncytial virus (RSV) prophylaxis. It has been evaluated in large-scale clinical studies, and has demonstrated efficacy in reducing the disease burden of RSV in high-risk infant populations. Motavizumab (MEDI-524, NUMAX, NISTmAb) has higher affinity and a longer half-life, was effective in reducing RSV hospitalization in high-risk full-term infants in the US, but was not licensed due to safety concerns (allergic reactions).
Species reactivityHRSV-A
ApplicationsResearch Grade Biosimilar
Host speciesHumanized
IsotypeIgG1, kappa
Expression systemMammalian Cells
ClonalityMonoclonal
TargetF, Fusion glycoprotein F0, Fusion glycoprotein F2, p27, Intervening segment, Pep27, Peptide 27, Fusion glycoprotein F1
Endotoxin levelPlease contact the lab for this information.
Purity>95% purity as determined by SDS-PAGE.
PurificationProtein A/G, purified from cell culture supernatant.
AccessionP03420
FormLiquid
Storage buffer0.01M PBS,pH7.4.
Stability and StorageUse a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C.
Alternate NamesMEDI-524,NUMAX,NISTmAb,CR9503,CAS:677010-34-3
BackgroundMotavizumab (MEDI-524) is an anti-human RSV (respiratory syncytial virus) monoclonal antibody. Motavizumab can be used in respiratory syncytial virus infection in high-risk infants research.
NoteFor research use only. Not for use in clinical or therapeutic applications.
Images
  • SEC-HPLC

    SEC-HPLC detection for Research Grade Motavizumab.

  • Bioactivity

    Detects F/Fusion glycoprotein F0 in indirect ELISAs.

References

Recommendation